The U.S. Food and Drug Administration today announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately. This is the latest step in an ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications (commonly known by the brand name Zantac). The agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of this impurity. As a result of this immediate market withdrawal request, ranitidine products will not be available for new or existing prescriptions or OTC use in the U.S
How Telehealth Saved A Patient's Life - Dr. Weber and Dr. Ramos share on USA TODAY!
“Cynthia Peeters’ stomach started hurting in mid-February as COVID-19 began dominating the news. By April, the pain was overwhelming, but she was too anxious about the virus to go to the doctor. Her gastroenterologist did a cellphone video visit with... Read More
Are you currently taking Humira? See how the COVID-19 pandemic may affect you.
Patients treated with Humira are at a heightened risk for developing serious infections. COVID-19 has proven to be quite infectious, as the number of cases are still expanding. At GI Alliance, we are dedicated to helping our patients understand... Read More